More data will provide more insight into the use of teprotumumab for PDD
As more data is collected on teprotumumab for use in thyroid eye disease (TED), we will have a better understanding of which subgroups respond better or worse to treatment, explained Robert G. Fante. , MD, FACS, President of the American Society for Ophthalmic Plastic and Reconstructive Surgery and Facial Plastic Surgeon and Aesthetic Surgeon, Fante Eye & Face Center in Denver, Colorado.
As more data is collected on teprotumumab treatment for thyroid eye disease (TED), we will have a better understanding of which subgroups respond better or worse to treatment, explained Robert G. Fante, MD, FACS, President of the American Society of Ophthalmic Plastic & Reconstructive Surgery and Facial Plastic and Cosmetic Surgeon, Fante Eye & Face Center in Denver, Colorado.
The pivotal studies for teprotumumab had quite small cohorts. What are the benefits we will see when we start getting larger patient population studies?
I think there will be a lot of benefits to this. Obviously, the studies were powerful enough to give us statistical significance for the FDA to take action and allow all of us to use this drug and feel that we have a reasonable chance of success.
That said, as we have larger cohorts and more information, we will have a lot more data; this will be useful to help us identify the subgroups for which it is most useful or the subgroups for which it is least useful, or if it turns out that there is a variation between men and women, for example, or between children and adults or if there are particular subtypes that we cannot identify clinically, for whom we decide that is the best therapy we have or maybe that there is something better.
Also, I suspect that as the research progresses, we will learn more about other similar types of drugs that may still be in development and may be useful. So I suspect the future is very bright, both for this drug and for our ability to use it effectively in patients as we get more data and have more controlled trials available to us. . And then also for the future of thyroid eye disease, that this will be the start of a new era in treatment where instead of just treating some of the more obvious issues and sort of secondarily treating the symptoms with things like surgery, we’ll have a way to prevent some of the problems, greatly limiting the burden on society, and obviously the burden on individual patients.